Week in Review: Week's Deals Create New China Life Science Alliances

Luye Medical Group will spend $300 million to bring up-to-date healthcare operations to a large public healthcare complex being built in Chongqing; Shanghai Kyee Technology raised $47 million in venture capital for its two mobile healthcare applications; Shanghai Mab-Venture booked $35 million in a Series A round for its biologic CRO/CMO business; BGI of Shenzhen led a $30 million Series A investment in Beijing Gene+ Technology, an oncology liquid biopsy company; Singlera Genomics, a San Diego-Shanghai genetic testing startup, raised $20 million in a Series A funding led by Lilly Asia Ventures; Hangzhou Liaison Interactive paid $20 million for a 62% stake in Beijing medical device maker Dehaier Medical; BioLineRx, an Israeli in-licensing company, established a joint venture with China's I-Bridge Capital to develop innovative therapies for China; Lee’s Pharm of Hong Kong and Beijing Shenogen Pharma will develop their two liver cancer drug candidates as a compound regimen; Monvida Pharma of San Francisco in-licensed China and Vietnam rights to TumorSelect® Paclitaxel from Cloaked Therapeutics of Mississippi. More details.... Stock Symbols: (HK: 2186) (SHZ: 2280) (NSDQ: DHRM) (NSDQ/TASE: BLRX) (HK: 950) Share this with colleagues: // //